Literature DB >> 28747989

Biophysical interaction between corticosteroids and natural surfactant preparation: implications for pulmonary drug delivery using surfactant a a carrier.

Yi E Wang1, Hong Zhang1,2, Qihui Fan1, Charles R Neal3, Yi Y Zuo1.   

Abstract

Intratracheal administration of corticosteroids using a natural pulmonary surfactant as a delivery vehicle has recently received significant attention in hopes of treating premature newborns with or at high risk for chronic lung disease. As a new practice, both the surfactant preparation used as the carrier and the corticosteroid delivered as the anti-inflammatory agent, and their mixing ratios, have not been standardized and optimized. Given the concern that corticosteroids delivered via a pulmonary surfactant may compromise its surface activity and thus worsen lung mechanics, the present study was carried out to characterize the biophysical interaction between a natural surfactant preparation, Infasurf, and two commonly used inhaled corticosteroids, budesonide and beclomethasone dipropionate (BDP). Based on surface activity measurements by the Langmuir balance and lateral film structure studied by atomic force microscopy, our findings suggest that when Infasurf is used as a carrier, a budesonide concentration less than 1 wt% of surfactant or a BDP concentration up to 10 wt % should not significantly affect the biophysical properties of Infasurf, thus being feasible for pulmonary delivery. Increasing corticosteroid concentration beyond this range leads to early collapse of the surfactant film due to increased film fluidization. Our study further suggests that different affinities to the surfactant films are responsible for the different behavior of budesonide and BDP. In addition to the translational value in treating chronic lung disease, this study may also have implications in inhaled steroid therapy to treat asthma.

Entities:  

Year:  2011        PMID: 28747989      PMCID: PMC5522965          DOI: 10.1039/c1sm06444d

Source DB:  PubMed          Journal:  Soft Matter        ISSN: 1744-683X            Impact factor:   3.679


  48 in total

1.  Natural surfactant combined with beclomethasone decreases oxidative lung injury in the preterm lamb.

Authors:  Carlo Dani; Iuri Corsini; Silvia Burchielli; Valentina Cangiamila; Mariangela Longini; Ferdinando Paternostro; Giuseppe Buonocore; Firmino F Rubaltelli
Journal:  Pediatr Pulmonol       Date:  2009-12

Review 2.  Recent advances in pulmonary drug delivery using large, porous inhaled particles.

Authors:  D A Edwards; A Ben-Jebria; R Langer
Journal:  J Appl Physiol (1985)       Date:  1998-08

Review 3.  Morphological basis of alveolar-capillary gas exchange.

Authors:  E R Weibel
Journal:  Physiol Rev       Date:  1973-04       Impact factor: 37.312

4.  Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia.

Authors:  C H Cole; T Colton; B L Shah; S Abbasi; B L MacKinnon; S Demissie; I D Frantz
Journal:  N Engl J Med       Date:  1999-04-01       Impact factor: 91.245

Review 5.  Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide.

Authors:  A R Boobis
Journal:  Respir Med       Date:  1998-07       Impact factor: 3.415

6.  A ToF-SIMS study of the lateral organization of lipids and proteins in pulmonary surfactant systems.

Authors:  Eleonora Keating; Alan J Waring; Frans J Walther; Fred Possmayer; Ruud A W Veldhuizen; Nils O Petersen
Journal:  Biochim Biophys Acta       Date:  2010-11-24

7.  Surface tension gradient driven spreading on aqueous mucin solutions: a possible route to enhanced pulmonary drug delivery.

Authors:  Kevin Koch; Beautia Dew; Timothy E Corcoran; Todd M Przybycien; Robert D Tilton; Stephen Garoff
Journal:  Mol Pharm       Date:  2011-01-20       Impact factor: 4.939

8.  Atomic force microscopy studies of functional and dysfunctional pulmonary surfactant films, II: albumin-inhibited pulmonary surfactant films and the effect of SP-A.

Authors:  Yi Y Zuo; Seyed M Tadayyon; Eleonora Keating; Lin Zhao; Ruud A W Veldhuizen; Nils O Petersen; Matthias W Amrein; Fred Possmayer
Journal:  Biophys J       Date:  2008-06-06       Impact factor: 4.033

9.  Effect of inhaled budesonide on surfactant protein expression in asthmatic mice.

Authors:  Zhi-Wei Yu; Jian-Hua Zhang
Journal:  Allergy Asthma Proc       Date:  2008 Sep-Oct       Impact factor: 2.587

10.  Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study.

Authors:  Michael W Sims; Ruth M Tal-Singer; Sonja Kierstein; Ali I Musani; Michael F Beers; Reynold A Panettieri; Angela Haczku
Journal:  Respir Res       Date:  2008-01-28
View more
  6 in total

1.  Calf Lung Surfactant Recovers Surface Functionality After Exposure to Aerosols Containing Polymeric Particles.

Authors:  Amir M Farnoud; Jennifer Fiegel
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-02-11       Impact factor: 2.849

Review 2.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

3.  In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration.

Authors:  Francesca Ricci; Chiara Catozzi; Francesca Ravanetti; Xabier Murgia; Francesco D'Aló; Natalia Macchidani; Elisa Sgarbi; Valentina Di Lallo; Federica Saccani; Marisa Pertile; Antonio Cacchioli; Silvia Catinella; Gino Villetti; Maurizio Civelli; Francesco Amadei; Fabio Franco Stellari; Barbara Pioselli; Fabrizio Salomone
Journal:  Pediatr Res       Date:  2017-08-23       Impact factor: 3.756

4.  Differential effects of cholesterol and budesonide on biophysical properties of clinical surfactant.

Authors:  Hong Zhang; Yi E Wang; Charles R Neal; Yi Y Zuo
Journal:  Pediatr Res       Date:  2012-02-15       Impact factor: 3.756

5.  Electronic cigarette vapor alters the lateral structure but not tensiometric properties of calf lung surfactant.

Authors:  Rebecca J Przybyla; Jason Wright; Rajan Parthiban; Saeed Nazemidashtarjandi; Savas Kaya; Amir M Farnoud
Journal:  Respir Res       Date:  2017-11-17

6.  An adverse outcome pathway for lung surfactant function inhibition leading to decreased lung function.

Authors:  Emilie Da Silva; Ulla Vogel; Karin S Hougaard; Jesus Pérez-Gil; Yi Y Zuo; Jorid B Sørli
Journal:  Curr Res Toxicol       Date:  2021-05-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.